On November 20, 2024 The Leukemia & Lymphoma Society (LLS) reported the company will present new data from its Beat AML Master Clinical Trial and Pediatric Acute Leukemia (PedAL) Master Clinical Trial at the 66th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (Press release, The Leukemia & Lymphoma Society, NOV 20, 2024, View Source;lymphoma-society-lls-data-at-ash-provides-glimpse-into-the-future-of-blood-cancer-treatment-302310609.html [SID1234648529]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The findings from LLS’s convened master clinical trials show great progress and are helping shape the treatment landscape for acute leukemias. Updated results show that more than half of a group of children with relapsed acute leukemias achieved remission after receiving a combination of treatments. Additional data indicate that IDH inhibitors as single agent or in combination with low-intensity therapies may be a viable treatment option for older adults with acute leukemias.
LLS will also support its more than 150 funded researchers, as well as more than a dozen current and former LLS Therapy Acceleration Program (TAP) biotech company partners, who will present the latest updates from their ongoing clinical trials.
"For 75 years, LLS has funded physician-scientists and researchers who take risks, think big and test bold ideas," says Lee Greenberger, Ph.D., LLS’s Chief Scientific Officer. "Our strategic investments have helped advance more than 70% of blood cancer treatments approved by the FDA over the past 20 years and I am encouraged to see how the latest data at ASH (Free ASH Whitepaper) will lead to remarkable advances for patients."
Health equity is also a major focus of findings from several investigators funded through the LLS Equity in Access and IMPACT grant programs, which:
Show that there’s significant underrepresentation of women and racial and ethnic minorities in clinical trial enrollment
Provide patient recommendations on how to address disparities in people living with multiple myeloma
Share insights on how to address barriers to opening clinical trials in a community-oncology setting
Demonstrate the disparities in access to care and services depending on the type of insurance coverage.
"LLS has an incredible track record of success across its research, health equity, patient advocacy, and education and support services," says E. Anders Kolb, M.D., The Leukemia & Lymphoma Society’s President and CEO. "The breadth of research we support every year at ASH (Free ASH Whitepaper) reinforces our commitment to improve and extend the lives of blood cancer patients and accelerate progress."
Gwen Nichols, M.D., LLS’s Chief Medical Officer, will join a panel at the Annual ASH (Free ASH Whitepaper) Clinicians in Practice luncheon on December 8, 2024, focused on the future of artificial intelligence in blood cancer.
Drs. Kolb, Nichols and Greenberger are available to provide perspectives on pivotal data presented at ASH (Free ASH Whitepaper), including the promise of menin inhibitors to change the leukemia treatment landscape.
Following is an overview of compelling data from LLS that will be presented at ASH (Free ASH Whitepaper):
Reshaping How Adults with Acute Myeloid Leukemia are Treated
Nearly 1,600 patients with AML have received genomic screening within seven days of diagnosis and more than 500 have enrolled in one of the many Beat AML precision treatment subtrials, which so far have targeted 15 distinct types of AML.
Patients enrolled in Beat AML have achieved improved survival and better quality of life compared to patients receiving standard-of-care chemotherapy.
Beat AML also recently opened its first clinical subtrial to investigate the safety and efficacy of lomonitinib (ZE46-0134) in patients with FLT3-mutated relapsed or refractory AML in partnership with Eilean Therapeutics.
These new findings from Beat AML subtrials will be presented at ASH (Free ASH Whitepaper):
Title & Poster Number
Date/Time
Location
Poster 1564 – Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
Saturday, Dec. 7, 2024
5:30-7:30 PM
San Diego Convention Center
Halls G-H
Poster 4324 – Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
Monday, Dec. 9, 2024
6:00-8:00 PM
San Diego Convention Center
Halls G-H
Poster 4325 – IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
Monday, Dec. 9, 2024
6:00-8:00 PM
San Diego Convention Center
Halls G-H
LLS Executive Research Strategy Lead Ashley Yocum, Ph.D., is available to discuss Beat AML findings.
Revolutionizing the Treatment and Care of Children with Blood Cancer
LLS’s PedAL is fundamentally revolutionizing how children with pediatric leukemia are being treated while building a foundation that addresses major roadblocks to care.
LLS will present updated findings from the PedAL Screening Trial (APAL2020SC), which is actively enrolling in the U.S., Canada, Australia, and New Zealand. This LLS-convened and led screening trial assesses individual clinical and biological characteristics that can inform a family’s choice of standard treatment or enrolling in a clinical trial.
In addition to the PedAL Screening Trial, a treatment trial is open across 74 international sites. LLS anticipates the opening of a second PedAL global treatment trial soon.
Title & Poster Number
Date/Time
Location
Poster 4233 – Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial
Monday, Dec. 9, 2024
6:00-8:00 PM
San Diego Convention Center
Halls G-H
Chief Medical Officer Gwen Nichols, M.D., is available to provide updates on LLS PedAL and provide perspective on important clinical data coming out of ASH (Free ASH Whitepaper).
Driving the Latest Blood Cancer Developments Through Research Funding
Blood cancer physician-scientists and researchers are transforming the way we treat this disease, but they cannot do this groundbreaking work alone. LLS is helping to lead this charge by funding some of the most innovative research projects around the world focused on bringing blood cancer patients much needed new treatments.
LLS currently provides more than $300 million in academic biomedical research grants to investigators across 16 countries and 30 U.S. states to accelerate how we treat all blood cancers. LLS recently announced its latest round of multi-year grants, which includes research into the development of leukemia in children with Down syndrome.
Here are some of the latest research advances across a variety of blood cancers that several LLS grantees will present at ASH (Free ASH Whitepaper):
Title & Poster Number
Date/Time
Location
Oral 969 – Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy
Monday, Dec. 9, 2024
5:00 PM
Manchester Grand Hyatt San Diego, Grand Hall B
Oral 321 – Machine Learning Derived Three-Parameter Prognostic Model for Survival in Patients with BPDCN
Saturday, Dec. 7, 2024
4:30 PM
Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH
Oral 1011 – Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Monday, Dec. 9, 2024
5:00 PM
Marriott Marquis San Diego Marina, Grand Ballroom 8-9
Oral 739 – Follicular Dendritic Cells Represent a Therapeutic Vulnerability in Early Follicular Lymphoma
Monday, Dec. 9, 2024
10:30 AM
Marriott Marquis San Diego Marina, Grand Ballroom 5-6
Oral 102 – Acute GvHD of the Gut Is Associated with Minor Histocompatibility Antigens Cross-Reactive Against Gut-Tropic Viral Epitopes
Saturday, Dec. 7, 2024
10:45 AM
San Diego Convention Center Ballroom 20CD
Oral 671 – A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
Sunday, Dec. 8, 2024
5:30 PM
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26
Oral 755 – JAK2V617F Mutant MPN Cells Support Parallel Evolution of Independent Leukemic Clones
Monday, Dec. 9, 2024
11:30 AM
Manchester Grand Hyatt San Diego, Grand Hall C
Oral 857 – A Multiomic Analysis of Waldenstrom’s Macroglobulinemia Identifies Three Subtypes of Disease Based on Impaired Plasma Cell Differentiation
Monday, Dec. 9, 2024
3:45 PM
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19
Poster 3127 – Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease
Sunday, Dec. 8, 2024
6:00-8:00 PM
San Diego Convention Center
Halls G-H
Addressing Healthcare Disparities Means a Better Future for Everyone with Blood Cancer
LLS believes every blood cancer patient and survivor should be able to access the care they need when they need it. LLS is addressing healthcare disparities to ensure everyone has a better future through three signature programs:
The Equity in Access Research Program, which provides funding for health services research that seeks to uncover and ultimately address the social, economic, and environmental disadvantages that stand in the way of patients with and survivors of a blood cancer accessing high-quality cancer care and services.
Influential Medicine Providing Access to Clinical Trials (IMPACT) provides funding to major cancer centers around the U.S. to collaborate with community-based hospitals and clinics to bring quality blood cancer clinical trials significantly closer to underrepresented patients.
Underrepresented Minority Medical Student (URM) Research programs, launched in 2023, aim to provide medical students from groups underrepresented in biomedical science the opportunity to participate in blood cancer research and benefit from mentorship that the program also provides. The URM program’s first grantee, Jennifer Lewis, is a co-author on an abstract that has developed a new CAR-T product that shows early promise in treating acute myeloid leukemia.
LLS proudly and gratefully acknowledges the leadership support of Royalty Pharma and the following companies for their support of the Equity in Access Research Program and other initiatives focused on reducing healthcare disparities in blood cancer care and treatment: AstraZeneca Pharmaceuticals LP, Lilly and Bristol Myers Squibb.
Title & Poster Number
Date/Time
Location
IMPACT Grants
Oral 784 – Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact
Monday, Dec. 9, 2024
11:15 AM
Marriott Marquis San Diego Marina, San Diego Ballroom AB
Poster 2322 – Chive-Impact: Establishing the Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE) Registry and Biorepository in Underserved Areas
Saturday, Dec. 7, 2024
5:30-7:30 PM
San Diego Convention Center
Halls G-H
Equity in Access
Oral 786 – Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer
Monday, Dec. 9, 2024
11:45 AM
Marriott Marquis San Diego Marina, San Diego Ballroom AB
Oral 792 – Impact of Fee-for-Service Versus Managed Care Medicare Insurance on the Quality of End-of-Life Care Among Older Adults with Blood Cancers
Monday, Dec. 9, 2024
11:45 AM
Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH
Health Services
Poster 5100 – Disparities in phase 2 and 3 clinical trial enrollment for hematologic malignancies
Monday, Dec. 9, 2024
6:00-8:00 PM
San Diego Convention Center
Halls G-H
Poster 5113 – Disparities in clinical trial participation among Medicare beneficiaries with hematologic malignancies from 2006 to 2019: a SEER-Medicare analysis
Monday, Dec. 9, 2024
6:00-8:00 PM
San Diego Convention Center
Halls G-H
Partner Projects
Poster 2383 – A Patient Perspective on Actionable Steps to Address Disparities in Healthcare Among US Patients with Multiple Myeloma
Saturday, Dec. 7, 2024
5:30-7:30 PM
San Diego Convention Center
Halls G-H
URM
Oral 371 – Development of CAR T Cells Targeting U5snRNP200 for the Treatment of Acute Myeloid and B-Lymphoid Leukemias
Saturday, Dec. 7, 2024
5:00 PM
Manchester Grand Hyatt San Diego, Grand Hall C
Senior Vice President of Education Services & Health Research Elisa Weiss, Ph.D., is available to provide perspective on health equity research presented at ASH (Free ASH Whitepaper).
Taking Risks to Accelerate the Development of Innovative Blood Cancer Therapies
LLS TAP provides funding to biotech companies to accelerate the development of innovative blood cancer treatments with the promise of changing the standard of care for blood cancer. As a strategic venture philanthropy program, LLS TAP can invest in research that venture capitalists find too risky.
Since 2017, five LLS TAP-supported therapies have been approved by the FDA or included in the National Comprehensive Cancer Network guidelines. Here are some of the latest research advances across a variety of blood cancers that several LLS TAP company partners will showcase at ASH (Free ASH Whitepaper):
Title & Poster Number
Date/Time
Location
Oral 214 – Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
Saturday, Dec. 7
2:45 PM
San Diego Convention Center, Ballroom 20CD
Oral 980 – Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization
Monday, Dec. 9, 2024
4:45 PM
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17
Oral 1008 – IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results
Monday, Dec. 9, 2024
5:45 PM
Manchester Grand Hyatt San Diego, Grand Hall D
Poster 2876 – ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction
Sunday, Dec. 8, 2024
6:00-8:00 PM
San Diego Convention Center
Halls G-H
Poster 3052 – Investigating the Novel Combination of the Innate Cell Engager (ICE) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study
Sunday, Dec. 8, 2024
6:00-8:00 PM
San Diego Convention Center
Halls G-H
Poster 4265 – Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study
Monday, Dec. 9, 2024
6:00-8:00 PM
San Diego Convention Center
Halls G-H
Poster 4395 – EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study
Monday, Dec. 9, 2024
6:00-8:00 PM
San Diego Convention Center
Halls G-H
Poster 4433 – Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors
Monday, Dec. 9, 2024
6:00-8:00 PM
San Diego Convention Center
Halls G-H